key: cord-0914971-9dwa0g57
authors: Lehner, Georg Franz; Klein, Sebastian Johann; Zoller, Heinz; Peer, Andreas; Bellmann, Romuald; Joannidis, Michael
title: Correlation of interleukin-6 with Epstein–Barr virus levels in COVID-19
date: 2020-11-23
journal: Crit Care
DOI: 10.1186/s13054-020-03384-6
sha: f748dde8e59cdc0abb2001ce70f3e509de357d78
doc_id: 914971
cord_uid: 9dwa0g57

nan

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) pneumonia with respiratory failure in a subset of infected patients. To date, it is unclear which factors trigger or cause the severe course of disease. Moreover, there is only limited evidence concerning extrapulmonary manifestations of COVID-19.

We observed that COVID-19 patients invasively ventilated in our intensive care unit (ICU) showed biochemical abnormalities that resemble hepatitis and pancreatitis typically caused by herpesviruses like Epstein-Barr virus (EBV) or cytomegalia virus (CMV). Moreover, a subgroup of COVID-19 patients exhibit a hyperinflammatory pattern similar to secondary hemophagocytic lymphohistiocytosis (sHLH) [1, 2] , a syndrome that can be triggered by viruses like EBV.

Thus, we speculated whether critically ill COVID-19 patients show evidence of EBV-or CMV-infection or reactivation and quantified EBV as well as CMV DNA levels in blood by PCR.

Herein, we report a retrospective analysis using data of the Tyrolean COVID-19 intensive care registry. We evaluated all COVID-19 patients that were treated between March 26, 2020, and April 20, 2020, in the Medical ICU at the Medical University Innsbruck, Austria, due to respiratory failure and required invasive ventilation (n = 20). Eighteen patients had at least one EBV and CMV PCR during ICU stay and were thus eligible for analysis. They were compared to eighteen consecutive invasively ventilated ICU patients without COVID-19.

We found that 78% of COVID-19 patients had EBV viremia, 39% even above 1000 IU/ml. Prevalence and levels of EBV viremia were significantly higher in COVID-19 patients compared to non-COVID-19 patients (44.4%, Pearson Chi-square p = 0.040, Mann-Whitney U test p = 0.022, SPSS 26 (IBM, Armonk, NY)).

In contrast, only 17% of COVID-19 patients and 5.6% of non-COVID-19 patients had evidence of CMV viremia, which was not significantly different between the groups (Pearson Chi-square p = 0.289). No correlations between viral load of EBV and blood levels of hepatic and pancreatic enzymes or cholestasis parameters were detected.

However, there was a significant correlation between EBV viremia and interleukin-6 (IL-6) level (Fig. 1 , r = 0.621, p = 0.006) in COVID-19 patients, but not in non-COVID-19 patients (r = − 0.195, p = 0.438, Spearman's rank-order correlation). Detailed patient characteristics are outlined in Table 1 . 

This is the first systematic report of EBV viremia in critically ill COVID-19 patients which revealed two important findings: First, COVID-19 patients have a higher prevalence of EBV viremia compared to non-COVID-19 patients. Second, levels of EBV viremia correlate with IL-6 in COVID-19 patients but not in non-COVID-19 patients.

Since EBV can induce immune dysregulation and expression of IL-6 in peripheral blood mononuclear cells (PBMCs) via deoxyuridine triphosphate nucleotidohydrolase (dUTPase) in vitro [3] , one might speculate that EBV acts as an additional inflammatory trigger in critically ill COVID-19 patients.

The observation that two patients without history of allergy but an EBV viremia above 1000 IU/ml developed a generalized maculopapular rash following administration of amoxicillin/clavulanate and piperacillin/tazobactam, further emphasizes the hypothesized immunological impact of EBV in this setting [4, 5] .

Although this observation was made in a limited number of patients in a retrospective analysis, the systematic approach based on registry data minimizes the risk of selection bias. Moreover, we compared COVID-19 patients to an appropriate control group. The findings concerning EBV and CMV viremia in the control group are in accordance with previously reported cumulative incidences (i.e., 48% and 18%, respectively) [6] .

These data suggest that EBV viremia is highly prevalent in COVID-19 patients with respiratory failure and associated with systemic inflammation as evidenced by high IL-6 levels. It remains to be elucidated whether EBV 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

COVID-19: consider cytokine storm syndromes and immunosuppression

EBVencoded dUTPase induces immune dysregulation: implications for the pathophysiology of EBV-associated disease

Rash associated with piperacillin/tazobactam administration in infectious mononucleosis

Antibiotic-induced rash in patients with infectious mononucleosis

Epidemiology of multiple herpes viremia in previously immunocompetent patients with septic shock

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Not applicable.

• fast, convenient online submission • thorough peer review by experienced researchers in your field • rapid publication on acceptance • support for research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year • At BMC, research is always in progress.

Ready to submit your research Ready to submit your research ? Choose BMC and benefit from:? Choose BMC and benefit from:viremia represents an epiphenomenon in COVID-19 or plays a pathogenetic role as additional trigger of a systemic inflammatory response in this setting. Authors' contributions GFL and MJ had the idea and developed the concept. GFL analyzed the data and wrote the manuscript. SJK, HZ, AP, and RB treated patients, collected data, and revised the manuscript. All authors read and approved the final manuscript.

There was no funding for this study.

No data are publicly available at this time.

This study was approved by the ethics committee of the Medical University Innsbruck (# 1099/2020).

Not applicable-manuscript contains no individual patient data.

None of the authors has any conflicts of interest to declare. Received: 28 August 2020 Accepted: 12 November 2020